SCHEMBL2127622

SCHEMBL2127622

Nc1nc(N)c2c(F)cccc2n1

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DHFR P00374 12/20 0.57
DCPS Q96C86 7/20 0.57
KCNH2 Q12809 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30912748 1.00 DHFR (0.57) DHFRDCPSKCNH2
SCHEMBL30918024 0.84 ACHE (0.46) DHFRDCPS
SCHEMBL30482724 0.84 ADORA2A (0.55) DHFRDCPSKCNH2
SCHEMBL30482730 0.84 DHFR (0.51) DHFRDCPSKCNH2
SCHEMBL13975880 0.81 KCNH2 (0.46) DHFRDCPSKCNH2
SCHEMBL21325635 0.81 ALDH1A1 (0.52) DHFRDCPSKCNH2
SCHEMBL21497074 0.81 ACHE (0.44) DHFRDCPSKCNH2
SCHEMBL2137593 0.80 DCPS (0.65) DHFRDCPSKCNH2
SCHEMBL10690347 0.79 DCPS (0.59) DHFRDCPSKCNH2
SCHEMBL1154559 0.78 DHFR (0.61) DHFRDCPSKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118142359-A Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof 万华化学集团股份有限公司 2024-06-07 CN claimed
CN-110797561-B Proton exchange membrane based on carbon quantum dots and preparation method thereof 上海博暄能源科技有限公司 2020-10-16 CN claimed
CN-111234505-A Environment-friendly damping rubber plate and preparation method thereof 谢强 2020-06-05 CN claimed
CN-110797561-A Proton exchange membrane based on carbon quantum dots and preparation method thereof 上海博暄能源科技有限公司 2020-02-14 CN claimed
CN-118142359-A Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof 万华化学集团股份有限公司 2024-06-07 CN disclosed
CN-110797561-B Proton exchange membrane based on carbon quantum dots and preparation method thereof 上海博暄能源科技有限公司 2020-10-16 CN disclosed
CN-111234505-A Environment-friendly damping rubber plate and preparation method thereof 谢强 2020-06-05 CN disclosed
CN-111234505-A Environment-friendly damping rubber plate and preparation method thereof 谢强 2020-06-05 CN disclosed
CN-110797561-A Proton exchange membrane based on carbon quantum dots and preparation method thereof 上海博暄能源科技有限公司 2020-02-14 CN disclosed
EP-2709989-B1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES JANSSEN SCIENCES IRELAND UC (IE) 2017-12-20 EP disclosed
EP-1014953-B1 FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS SUGEN INC (US) 2012-04-25 EP disclosed
CN-100478364-C Ethylene polymer and molded article obtained therefrom MITSUI CHEMICALS INC (JP) 2009-04-15 CN disclosed
US-20010014679-A1 Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds TANG PENG C (US) 2001-08-16 US disclosed
US-20010012844-A1 Formulations for hydrophobic pharmaceutical agents SHENOY NARMADA (US) 2001-08-09 US disclosed
US-6248771-B1 MIXTURE CONTAINING SURFACTANT; ANTIPROLIFERATIVE AGENTS; KINASE INHIBITOR SUGEN, INC. 2001-06-19 US disclosed
US-6204267-B1 Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds SUGEN, INC. 2001-03-20 US disclosed
EP-1014953-A2 FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS Sugen, Inc. (US) 2000-07-05 EP disclosed
EP-0981519-A1 METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS Sugen, Inc. (US) 2000-03-01 EP disclosed
WO-1998050370-A1 METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS SUGEN, INC. (US) 1998-11-12 WO disclosed
WO-1998038984-A2 FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS SUGEN, INC. (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010012844-A1 Formulations for hydrophobic pharmaceutical agents ABCG2, SLC7A5, SLCO4C1 DHFR 420/4885DCPS 4329/4885KCNH2 815/4885
US-20010014679-A1 Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds RAF1, STK3, MKNK1 DHFR 1842/4885DCPS 3645/4885KCNH2 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.